Title: Vical to Present at Upcoming Investor Conferences SAN
DIEGO, Sept. 5 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced
that its presentation at the UBS Global Life Sciences Conference will be webcast live on
Monday, September 24, 2007, at 1:30 p.m. Eastern Time. Vical's President and Chief
Executive Officer, Vijay B. Samant, will provide an overview of the company's
technologies, development programs, and strategic partnerships. The webcast will be
available live and archived through the events page at http://www.vical.com.
The company's presentations at the following conferences will not be webcast:
-- BioCentury NewsMakers in the Biotech Industry (New York, September 6),
-- Merriman Curhan Ford Investor Summit 2007 (San Francisco, September
17-18).
About Vical
Vical researches and develops biopharmaceutical products based on its patented DNA
delivery technologies for the prevention and treatment of serious or life-threatening
diseases. Potential applications of the company's DNA delivery technology include DNA
vaccines for infectious diseases or cancer, in which the expressed protein is an
immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system
stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic
growth factor. The company is developing certain infectious disease vaccines and cancer
therapeutics internally. In addition, the company collaborates with major pharmaceutical
companies and biotechnology companies that give it access to complementary technologies or
greater resources. These strategic partnerships provide the company with mutually
beneficial opportunities to expand its product pipeline and address significant unmet
medical needs. Additional information on Vical is available at http://www.vical.com.
This press release contains forward-looking statements subject to risks and
uncertainties that could cause actual results to differ materially from those projected.
Forward-looking statements include statements about the company's focus, collaborative
partners, product candidates, and developmental status. Risks and uncertainties include
whether any product candidates will be shown to be safe and efficacious in clinical
trials, the timing of clinical trials, whether Vical or its collaborative partners will
seek or gain approval to market any product candidates, the dependence of the company on
its collaborative partners, and additional risks set forth in the company's filings with
the Securities and Exchange Commission. These forward-looking statements represent the
company's judgment as of the date of this release. The company disclaims, however, any
intent or obligation to update these forward-looking statements.
Contacts: Investors: Media:
Alan R. Engbring Susan Neath
Vical Incorporated Porter Novelli Life Sciences
(858) 646-1127 (619) 849-6007
Website: http://www.vical.com
SOURCE Vical Incorporated
-0- 09/05/2007
/CONTACT: investors, Alan R. Engbring of Vical Incorporated,
+1-858-646-1127; or media, Susan Neath of Porter Novelli Life Sciences,
+1-619-849-6007, for Vical Incorporated/
/Web site: http://www.vical.com /
(VICL)
CO: Vical Incorporated
ST: California
IN: HEA BIO
SU: TDS CCA
CS-SM
-- LAW040 --
7655 09/05/2007 06:30 EDT http://www.prnewswire.com
|